Novel Health Strategies team is presenting nineteen studies at ISPOR 2103 Annual Meeting in New Orleans on market access strategy, pricing and health economic and outcomes research trends.

These studies were led by Novel Health team and are good examples of wide breadth and depth of our expertise.

In-person replays of all presentations are available upon request.


Meta-Analysis for Efficacy of Romiplostim for Treatment of ITP

Trends in Cost Effectiveness of High Budget Impact Products

PROs in Glaucoma a Systematic Review

PROs in Chronic Myeloid Leukemia: A Systematic Review

PROs in Castration-Resistant Prostate Cancer: A Systematic Review

Meta-Analysis For Efficacy of Etanercept For Treatment of Psoriatic Arthritis

Novel Electronic PROs Tool for Prostate Cancer Patients

Budget Impact Model for CTCL

Systematic Review of Anti-VEGF Therapies for Metastatic CRC

In-Patient Hospitalization Trends for CKD in the United States

Meta-Analysis for Safety of Dabigatran and Warfarin for Treatment of Atrial Fibrillation


Reimbursement and Market Access of MS Products in the United States

Cancer Drug Pricing Trends in the US and the UK (2011-2013)

Novel Reimbursement Models for Cancer Drug Market Access (2010-2013)

Trends in Use of Health Economic Evidence for Developing Clinical Guidelines

Review of France's Transparency Committee's 2011-2012 Assessments

Pricing and Reimbursement of Targeted Cancer Therapies in Russia (2011-2012)

Biosimilars Pricing Dynamics in Big Five European Union Countries (2011-2012)

Role of Subgroup Analyses for Health Technology Assessments